The logos of the Danish drug manufacturer Novo Nordisk, manufacturer of the successful diabetes and the treatments for Ozempic and Wegovy weight loss is seen outside therm Building as the company presents the annual report in Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.
Mads Claus Rasmussen | AFP | Getty images
Novo Nordisk On Wednesday, he marked the promising results of the trials in the late stage for his new obesity treatment of Cagrilinitidas, since the Danish pharmaceutical giant looks for a next generation alternative to his successful medicine in weight loss.
The early analysis of a redefinir 1 phase 3 rehearsal showed that Cagrilintide monotherapy injection, once a week, helped patients reduce their weight by 11.8% on average after 68 weeks, compared to 2.3% for placebo, the company said.
Cagrilintide is a nascent form of weight loss treatment that differs from existing LPG-1, such as Wegovy and Eli Lilly's Zepbound by Eli Lilly. The analogous of amiline of prolonged action that works imitating a hormone that is secreted jointly with insulin in the pancreas to increase satiety.
The drug manufacturer also pointed out the largest treatment tolerability profile, describing it as “well tolerated” with the most common side effects that are gastrointestinal and mainly “mild to moderate.”
Novo Nordisk's shares increased 1.3% at 11:15 am, London time, shortly after the findings were published.
“In our clinical trials, Cagrilintide has provided substantial weight loss, differently compared to approved obesity medications, and seems well tolerated,” said Martin Holst Lange, executive scientific director of Novo Nordisk and executive vice president of Research and Development, in a statement.
“We are excited that these data, the data of the first phase 3 of a next -generation amiline therapy, show promise and hope to further investigate Cagrilintid's potential in the dedicated renewal program of phase 3,” Lange added.
Novo Nordisk is looking for a next -generation obesity treatment after the fugitive success of its Ozempic diabetes and full obesity treatments have recently been pressed for supply limitations and greater competition of compound medication manufacturers.
Drug manufacturers also seek alternative treatments for patients fighting for LPG-1 in the long term. Roche and Zealand Pharma are also developing an analogous amiline obesity treatment known as Petrelintide.
Investors were previously disappointed by the results of the latest stage tests for Cagrisema, a combined therapy that combines semaglutida, the active ingredient in Wagovy, together with Cagrilintide.
However, Soren Lontoft, a pharmaceutical capital analyst at SydBank, told CNBC that the secondary effect profile was perhaps the most promising aspect of the new treatment.
“The secondary effect profile for Cagrilintide is of greater interest than weight loss. A more favorable secondary effect profile (with low interruption rate) than Wogovy and Zepbound is what I am looking for,” said Lontoft by email on Tuesday.
The results of the sub -analysis essay, which were presented in the European Association for the study of the Diabetes Congress in Vienna, Austria, evaluated adult patients with obesity or overweight and comorbidity related to weight without diabetes.
A phase 3 renewal trial, which investigates the effectiveness and safety of the medication in patients with obesity or who were overweight, but without associated comorbidities, is scheduled to begin at the end of 2025.
